ARA:NYE-American Renal Associates Holdings, Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.40B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

-3.61 (-0.74%)

USD191.04B 24.46 16.33
DHR Danaher Corporation

-0.11 (-0.04%)

USD183.37B 40.38 23.58
DHR-PA Danaher Corporation

+67.86 (+4.04%)

USD154.42B 263.72 N/A
PHG Koninklijke Philips N.V

-2.04 (-3.84%)

USD49.63B 21.11 33.10
IQV IQVIA Holdings Inc

-6.64 (-2.70%)

USD46.89B 116.50 25.76
A Agilent Technologies, Inc

-1.91 (-1.30%)

USD44.58B 49.14 30.91
MTD Mettler-Toledo International I..

-15.18 (-1.11%)

USD31.41B 53.45 34.54
LH Laboratory Corporation of Amer..

+0.01 (+0.00%)

USD25.44B 13.39 6.81
WAT Waters Corporation

-3.85 (-1.11%)

USD21.38B 35.09 24.52
CRL Charles River Laboratories Int..

-4.08 (-1.14%)

USD17.98B 48.59 24.74

ETFs Containing ARA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -14.04% 5% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.04% 5% F 7% F
Risk Return Profile  
Volatility (Standard Deviation) 32.32% 25% F 19% F
Risk Adjusted Return -43.43% 5% F 13% F
Market Capitalization 0.40B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 154.10 N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 10.25 N/A N/A N/A N/A
EV/EBITDA 9.37 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 17.51% N/A N/A N/A N/A
Return on Invested Capital 13.88% N/A N/A N/A N/A
Return on Assets 4.35% N/A N/A N/A N/A
Debt to Equity Ratio -681.00% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.91 N/A N/A N/A N/A
Short Percent 4.43% N/A N/A N/A N/A
Beta 1.11 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.